Associated tags: Blood pressure, Hypertension, Horner's syndrome, Glaucoma, Headache, FDA, Eye injury, Xanthine oxidase inhibitor, Patient, Pharmaceutical industry, Oxymetazoline, Aneurysm, Stroke, Blepharoplasty, Myasthenia gravis, Eye, Ptosis, Phosphorus, Beta blocker, Cardiovascular disease
Blood pressure,
Heart,
Pressure,
Blepharoplasty,
Bureau of Oceans and International Environmental and Scientific Affairs,
Stroke,
Ptosis,
Eye,
Myasthenia gravis,
Brain,
Prostate,
Aneurysm,
Doctor of Philosophy,
Hypertension,
Telecanthus,
Beauty,
Eyelid,
Patient,
Xanthine oxidase inhibitor,
Risk,
Eye injury,
Cover My Eyes (Pain and Heaven),
Dry,
FDA,
Headache,
Glaucoma,
Safety,
Mouth,
Horner's syndrome,
GameChanger,
Pharmaceutical industry,
Telescopic sight,
Medical device,
Veterinary medicine,
Nursing,
Oxymetazoline BRIDGEWATER, N.J., March 31, 2023 /PRNewswire-PRWeb/ -- RVL Pharmaceuticals announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner in the professional treatment category as "Best Eye Drop for Drooping Lids" in the NewBeauty 13th Annual Beauty Awards. Upneeq is FDA approved for the treatment of acquired blepharoptosis (droopy eyelids) in adults. It is the second consecutive win for the brand. Upneeq® was awarded the "Best Innovation" in 2022 by this definitive authority in beauty. The 13th Annual NewBeauty Awards issue hits newsstands on April 4, 2023.
Key Points:
- BRIDGEWATER, N.J., March 31, 2023 /PRNewswire-PRWeb/ -- RVL Pharmaceuticals announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner in the professional treatment category as "Best Eye Drop for Drooping Lids" in the NewBeauty 13th Annual Beauty Awards.
- The 13th Annual NewBeauty Awards issue hits newsstands on April 4, 2023.
- The most common adverse reactions with Upneeq (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.
- The most common adverse reactions with UPNEEQ (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.
Shape,
Hope,
Glaucoma,
Xanthine oxidase inhibitor,
Headache,
SHAPE,
Nasdaq,
Aneurysm,
Woman,
Ptosis,
Blood pressure,
Beta blocker,
Stroke,
Myasthenia gravis,
Shape (magazine),
Cardiovascular disease,
Eye,
Hypotension,
Metabolism,
Patient,
Risk,
FDA,
Industry,
The Company,
Horner's syndrome,
Eye injury,
Ophthalmoparesis,
Skin,
Superior tarsal muscle,
Blepharoplasty,
Orthostatic hypotension,
Focal neurologic signs,
Health,
Beauty,
Mark (given name),
Glycosidic bond,
Orbit,
Involuntary muscle,
Solution,
Goal,
Duane syndrome,
Motivation,
Hypertension,
Pharmaceutical industry,
Medical device,
Phosphorus,
Oxymetazoline Upneeq was selected as the winner of "Best Professional Treatment Product" in the "Shape Healthy Beauty Awards," the annual awards conducted by Shape Magazine out digitally and in the May issue.
Key Points:
- Upneeq was selected as the winner of "Best Professional Treatment Product" in the "Shape Healthy Beauty Awards," the annual awards conducted by Shape Magazine out digitally and in the May issue.
- About Shape / Shape Healthy Skin Awards - SHAPE Magazine has been an authoritative voice speaking directly to women who lead an active lifestyle, rooted in the science-backed expertise of editors and contributing board of advisors.
- RVL Pharmaceuticals plc RVL Pharmaceuticals plc(Nasdaq: RVLP) is a specialty pharmaceutical company focused exclusively on commercializing Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%.
- Upneeq is the first non-surgical treatment option approved by the FDA for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults.
Duane syndrome,
Company,
Ophthalmoparesis,
Orthostatic hypotension,
Risk,
Blepharoplasty,
Metabolism,
Headache,
Blood pressure,
U.S. FDA,
EVP,
Myasthenia gravis,
Glaucoma,
Glycosidic bond,
Patient,
Aneurysm,
Focal neurologic signs,
Cardiovascular disease,
Hypertension,
Industry,
Stroke,
Oxymetazoline,
Beta blocker,
Nasdaq,
Ptosis,
Mark (given name),
Horner's syndrome,
Xanthine oxidase inhibitor,
Orbit,
Hypotension,
FDA,
Education,
Eye,
Eye injury,
Pharmaceutical industry,
Phosphorus,
Leptodeira BRIDGEWATER, N.J. , April 6, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (Nasdaq: RVLP) announced today that its U.S. FDA approved acquired blepharoptosis (ptosis) drug UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of a "Best in Innovation" award in the 12th Annual Beauty Awards conducted by New Beauty, a Sandow Publication.
Key Points:
- New Beauty, a trend-driven education-powered quarterly published resource and website, has been a leader in the aesthetic space since its launch in 2005.
- New Beauty Features Editor, Tatiana Bido, said of the non-surgical option to treat adults with acquired ptosis, "UPNEEQ is an instant eye-lifter for adults with acquired ptosis or low-lying eyelids.
- "We are thrilled to be acknowledged by New Beauty with an Innovation Award for UPNEEQ," said JD Schaub, EVP & Chief Operating Officer.
- Industry support and validation like this award from New Beauty is further proof of concept."
